Sign In
Buy CAPR
$25.33
-0.680 (-2.61%)
At Close: Jun 10, 2026
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Capricor Therapeutics, Inc. (CAPR)
10:38am, Friday, 18'th Jul 2025
NEW YORK, July 18, 2025 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Southern District of C
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
07:56pm, Thursday, 17'th Jul 2025
LOS ANGELES--(BUSINESS WIRE)---- $CAPR--CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm.
Shareholder Alert: Robbins LLP Informs Investors of the Capricor Therapeutics, Inc. Class Action
06:37pm, Thursday, 17'th Jul 2025
SAN DIEGO, July 17, 2025 (GLOBE NEWSWIRE) -- Robbins LLP informs stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Capricor Therapeutics, Inc. (NAS
ATLANTA, July 17, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR). The lawsuit alleges that
NEW YORK, July 17, 2025 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Capricor The
BREAKING: Capricor Therapeutics Sued For Securities Fraud; Investors Should Contact Block & Leviton to Potentially Recover Losses
04:46pm, Thursday, 17'th Jul 2025
Block & Leviton announces that a securities fraud lawsuit has been filed against Capricor Therapeutics (Nasdaq: CAPR). Investors should contact the firm.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR
10:00am, Thursday, 17'th Jul 2025
NEW YORK , July 17, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ: CAPR). Such investors are
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Capricor (CAPR) To Contact Him Directly To Discuss Their Options
Wolf Popper LLP Announces Investigation on Behalf of Capricor Therapeutics, Inc. Investors
04:14pm, Monday, 14'th Jul 2025
NEW YORK, July 14, 2025 (GLOBE NEWSWIRE) -- Wolf Popper LLP is investigating potential claims on behalf of purchasers of Capricor Therapeutics, Inc. (“Capricor”) common stock (NASDAQ: CAPR).
FDA Rejects CAPR's Cell Therapy BLA for Genetic Disorder, Stock Tanks
12:35pm, Monday, 14'th Jul 2025
Capricor slumps 33% as the FDA rejects its BLA for DMD drug, deramiocel, citing lack of effectiveness data and CMC issues.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Capricor Therapeutics, Inc. - CAPR
10:00am, Monday, 14'th Jul 2025
NEW YORK, July 14, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR). Such in
Capricor Therapeutics: Buying Opportunity Following FDA's Complete Response Letter
07:43am, Monday, 14'th Jul 2025
Capricor Therapeutics's dip caused by the Complete Response Letter is a buying opportunity considering the readout of HOPE-3 within 2-3 months. Based on HOPE-2 data and the expected course of Duchenne
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR
10:00am, Saturday, 12'th Jul 2025
NEW YORK , July 12, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ: CAPR). Such investors are
OAKLAND, Calif.--(BUSINESS WIRE)---- $CAPR #CAPR--Shares of Capricor Therapeutics, Inc. plunged over 30% in intraday trading on Friday, July 11, 2025, after the U.S. Food and Drug Administration rejec
INVESTOR ALERT: Investigation of Capricor Therapeutics, Inc. (CAPR) Announced by Holzer & Holzer, LLC
01:00pm, Friday, 11'th Jul 2025
ATLANTA, July 11, 2025 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR) complied with federal securiti
